BIBW 2992 (Afatinib) and Vinorelbine

NCT01531764 | Terminated Phase 2

• 1 other identifier: 1200.137
• Study Type: interventional
• Target: 2
• Locations: 1 country
• Sites: 12

Brief Summary

This open-label, single-arm, multicentre phase II trial will be performed in patients with intermediate HER2-positive, metastatic breast cancer (MBC)pretreated with anthracyclines and one first-line therapy in the metastatic setting. The main objective of the trial is to evaluate the efficacy and safety of BIBW 2992 in combination with vinorelbine in patients with intermediate HER2-positive MBC. If this trial shows promising results, further studies to evaluate the benefit of BIBW 2992 in combination with chemotherapy in this subgroup of intermediate HER2-positive patients with MBC are warranted. Patients will be followed until progression. After progression, for the purpose of analysing overall survival, information on vital status and subsequent treatment will be collected. The primary objective is to determine the 6-month progression free survival rate of BIBW 2992 and vinorelbine i.v. in patients with metastatic, HER2 IHC 2+, HER2 FISH-negative breast cancer. BIBW 2992 in combination with vinorelbine will provide a suitable combination to test the hypothesis that patients with metastatic breast cancer whose tumours are HER2 2+ by immunohistochemistry, but negative by fluorescence in-situ hybridisation (FISH) will benefit from a combination of a cytotoxic agent, i.e. vinorelbine, plus the dual irreversible EGFR/HER2-tyrosine kinase inhibitor BIBW 2992.

Conditions

Carcinoma Breast Stage IV

Keywords

Metastatic breast cancer; intermediate HER2 expression; Afatinib

Outcome Measures

Primary Outcomes (1)

• Progression-free survival based on tumor imaging according to RECIST 1.1 criteria.

  The primary objective is to determine the 6-month Progression free survival rate of BIBW 2992 and vinorelbine i.v. in patients with metastatic, HER2 IHC 2+, HER2 FISH-negative breast cancer. The analysis will be based upon the evaluation of tumour imaging. Disease progression will be evaluated according to the RECIST 1.1 criteria.

  6 months defined as the time from the date of treatment start

Secondary Outcomes (2)

• Overall survival including assessment of objective response rate and time to progression.

  From start of treatment until the date of first documented progression or death from any cause, whichever came first, assessed approximately up to 24 months.

• Number, intensity and incidence of adverse events

  Start of treatment up to 28 days after the last administration trial medication.

Interventions

BIBW 2992 in combination with vinorelbine DRUG

Patients will receive BIBW 2992 and vinorelbine chemotherapy. BIBW 2992: 40 mg oral (tablet) once daily Vinorelbine: 25 mg/m² on days 1 \& 8 in a 3-weekly course, intravenous, short infusion of about 10 minutes

Also known as: Afatinib

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Female patients ≥ 18 years
• Histologically confirmed diagnosis of intermediate HER2-overexpressing breast cancer
• Stage IV metastatic disease
• Must have received anthracycline-based chemotherapy for adjuvant treatment of breast cancer or first-line treatment of metastatic breast cancer
• Must have received one first-line chemotherapy for metastatic breast cancer
• Must have (archived) tumour tissue sample available for central re- assessment of HER2 status and prove to be intermediate HER2-positive. HER2 intermediate status is defined as IHC 2+ and FISH-negativity.
• Must have at least one measurable lesion according to RECIST 1.1. Patient with only skin lesions will not be eligible.
• Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.
• Life expectancy of at least six (6) months.
• Written informed consent that is consistent with ICH-GCP guidelines.
• Must be eligible for treatment with BIBW 2992 and vinorelbine.

You may not qualify if:

• \. Prior treatment with EGFR/HER2-targeted tyrosine kinase inhibitors, i.e. lapatinib
• Prior treatment with vinorelbine
• Known pre-existing interstitial lung disease
• Radiotherapy, chemotherapy, hormone therapy, immunotherapy or surgery (other than biopsy) within 4 weeks (2 weeks for hormone therapy) prior to start of treatment with BIBW 2992 and vinorelbine.
• Active brain metastases
• Any other current malignancy or malignancy diagnosed within the past five (5) years (other than non-melanomatous skin cancer and in situ cervical cancer).
• Significant or recent acute gastrointestinal disorders with diarrhoea as a major symptom, e.g. Crohn's disease, malabsorption or CTC grade ≥ 2 diarrhoea of any aetiology.
• History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of ≥3, unstable angina or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to start of study treatment.
• Cardiac left ventricular function with resting ejection fraction of less than 50 %.
• Any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the test drug.
• Laboratory values according to specified ranges.
• Women of childbearing potential, unwilling to use a medically acceptable method of contraception during the trial.
• Pregnancy or breast-feeding.
• Patients unable to comply with the protocol.
• Known hepatitis B infection, known hepatitis C infection or known HIV carrier.

Sponsors & Collaborators

• University of Magdeburg: lead
• Boehringer Ingelheim: collaborator

Study Sites (12)

Klinikum St. Marien Amberg

Amberg, Bavaria, 92224, Germany

Location

Hämato-Onkologische Schwerpunktpraxis

München, Bavaria, 80638, Germany

Location

Caritas-Krankenhaus, Onkologisches Zentrum Regensburg

Regenburg, Bavaria, 93053, Germany

Location

Internistische Praxisgemeinschaft Eppendorf

Hamburg, Hamburg, 20249, Germany

Location

OncoResearch Lerchenfled UG

Hamburg, Hamburg, 22081, Germany

Location

Gynäkologische Praxis

Hildesheim, Lower Saxony, 31134, Germany

Location

Schwerpunktpraxis für Hämatologie und Onkologie

Bottrop, North Rhine-Westphalia, 46236, Germany

Location

Universitätsklinikum Frauenklinik Düsseldorf

Düsseldorf, North Rhine-Westphalia, 40225, Germany

Location

Klinikum Chemnitz gGmbH

Chemnitz, Saxony, 09116, Germany

Location

Otto-von-Guericke-Universität Frauenklinik Magdeburg

Magdeburg, Saxony-Anhalt, 39108, Germany

Location

Praxisklinik Krebsheilkunde für Frauen / Brustzentrum

Berlin, State of Berlin, 10367, Germany

Location

Onkologisches Zentrum Süd, Vivantes Tumorzentrum

Berlin, State of Berlin, 12351, Germany

Location

MeSH Terms

Conditions

Breast Neoplasms

Interventions

Afatinib; Vinorelbine

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Amides; Organic Chemicals; Quinazolines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Vinca Alkaloids; Secologanin Tryptamine Alkaloids; Indole Alkaloids; Alkaloids; Indoles; Indolizidines; Indolizines

Study Officials

• Joachim Bischoff, MD

  Otto-von-Guericke-Universität Magdeburg, Germany

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: February 9, 2012
• First Posted: February 13, 2012
• Study Start: July 1, 2012
• Primary Completion: September 1, 2013
• Study Completion: September 1, 2013
• Last Updated: October 18, 2013

Record last verified: 2012-02

Locations

DE (12)